On May 24, 2022 Travecta Therapeutics, Pte Ltd., a private biopharmaceutical company pioneering transformative treatments for serious neurological conditions by utilizing a natural transport system in the blood-brain barrier ("BBB") as a novel delivery platform, reported that Donald C. Manning, MD, PhD, Chief Medical Officer and Head of Research and Development, will present at the 2022 BIO International Convention occurring June 13-16, 2022 in San Diego, CA (Press release, Travecta Therapeutics, MAY 24, 2022, View Source [SID1234614986]). The presentation will take place on Monday, June 13, 2022 at 12:30 PM PDT in Theater 2 in the San Diego Convention Center.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Dr. Manning will provide an overview of the Company’s platform technology, which came out of David Silver’s lab at Duke-NUS Medical School and is based on the discovery that the MFSD2A protein, in the BBB, can transport drugs into the central nervous system ("CNS") when attached to modified fatty acids. Travecta uses this platform to select and screen active drugs with poor BBB penetration and conjugate them with transport-enabling structures to facilitate BBB transport via MFSD2A and specific release of active drug in the CNS.

Dr. Manning will also discuss recent development updates across multiple pipeline programs that have been discovered using the Travecta platform, including TVT-004, a conjugate of the endocannabinoid anandamide with potential to treat a broad range of neurologic disorders, and additional programs with a range of neuro-inflammation and neuro-oncology applications.

"We have made tremendous progress on development of the Travecta platform and pipeline programs thus far in 2022," noted Dr. Manning. "BIO is an excellent opportunity to share this progress as we move our lead program toward the clinic by the end of the year."

Added Dr. Charles Ryan, PhD, President and Chief Executive Officer, "Because the Travecta platform has the flexibility to enhance the CNS access of a broad range of compounds, partnering is a core element of our strategy, and BIO is an ideal environment for us to identify new collaboration opportunities for the creation of next-generation CNS-penetrant therapeutics."

On May 24, 2022 Sysmex Inostics, a global leader in the liquid biopsy revolution, reported that it has expanded its offering of CLIA-validated tests to include AML-SEQ, a focused panel to detect mutations of the three most prevalent genes found in Acute Myeloid Leukemia (AML) – IDH1/2 & NPM1 (Press release, Sysmex Inostics, MAY 24, 2022, View Source [SID1234614984]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

AML-SEQ rounds out the company’s AML Laboratory Developed Test (LDT) offerings with a less expensive test compared to the broader AML-MRD-SEQ panel launched in October 2021. AML-MRD-SEQ is a more extensive panel for the detection of measurable residual disease (MRD) in 68 regions across 20 genes including the clinically established IDH1/2 and NPM1.

"We envision investigators and eventually physicians using AML-SEQ and AML-MRD-SEQ as a one-two-punch in the fight against AML and AML MRD. We are committed to developing tools to support the fight against this devastating disease. We must support management of patients suffering from AML by providing the accurate and sensitive detection of AML biomarkers," said Shinichi Sato, CEO of Sysmex Inostics, Inc.

AML-SEQ adds to the portfolio of ultra-sensitive Plasma-Safe-SeqS technology NGS tests available through Sysmex Inostics’ CLIA lab services in Baltimore, Maryland.

Joins Foundation for the National Institutes of Health Biomarkers Consortium

The FNIH consortium combines significant public and private organizations to develop AML MRD guidelines, establish methods for MRD detection, and achieve better measures for clinical trial design and drug development. Project partners include the National Cancer Institute (NCI), the National Heart Lung and Blood Institute (NHLBI), the U.S. Food and Drug Administration (FDA), several award-winning cancer institutions and leading pharmaceutical and diagnostic companies. For more information about the FNIH AML-MRD Consortium click here.

According to the National Cancer Institute (NCI), an estimated 20,050 new AML cases will be diagnosed in the United States in 2022.1 Rising incidence of cancer and increasing preference of noninvasive treatments is driving the quick expansion of the liquid biopsy market. Globally, the liquid biopsy market is to achieve an annual growth rate of more than 18% over the next few years, reaching $5.8 billion by 2026.2

On May 24, 2022 Merck (NYSE: MRK), known as MSD outside the United States and Canada, reported that the Board of Directors has declared a quarterly dividend of $0.69 per share of the company’s common stock for the third quarter of 2022 (Press release, Merck & Co, MAY 24, 2022, View Source [SID1234614982]). Payment will be made on July 8, 2022 to shareholders of record at the close of business on June 15, 2022.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

On May 24, 2022 MaaT Pharma (EURONEXT: MAAT – the "Company"), a French clinical-stage biotech and a pioneer in the development of Microbiome Ecosystem Therapies dedicated to improving survival outcomes for patients with cancer reported that it will host its first R&D Day for analysts and investors to be held virtually on Tuesday, June 7th, 2022 from 4:00 pm CEST (10:00 am EST) to 6:00 pm CEST (12:00 pm EST) (Press release, MaaT Pharma, MAY 24, 2022, View Source [SID1234614981]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

MaaT Pharma’s speakers will discuss the microbiome potential in cancer therapy and the latest clinical results of MaaT013 and MaaT033. They will also present the Company’s innovative proprietary drug discovery platform, the next generation of products MaaT03X and the construction of Europe’s largest cGMP manufacturing facility for Microbiome Ecosystem Therapies.

In addition to the presentations by MaaT Pharma’s senior team, the R&D Day will feature talks from world renowned scientists and physicians including:

Joël Doré – Research Director, Director of INRAE and Scientific Advisor at MaaT Pharma, France
Ernst Holler, M.D. – Senior Professor on Clinical and Experimental Allo-HSCT, Department of Internal Medicine, University Hospital Center Regensburg, Germany
Florent Malard, M.D. – Professor of Hematology, Saint Antoine Hospital (AP-HP) and Sorbonne University
Mohamad Mohty, M.D. – Professor, Sorbonne University and Head of the Clinical Hematology and Cellular Therapy Department, Saint-Antoine Hospital (AP-HP), France
Hassane Zarour, M.D. – Professor of Medicine, Immunology and Dermatology, University of Pittsburg, James and Frances McGlothlin Chair in Melanoma Immunotherapy Research
"MaaT Pharma’s inaugural R&D Day is an opportunity to bring together world-renowned scientists and our talented internal team to share MaaT Pharma’s innovative research and highlight our unique positioning in the microbiome space," said Hervé Affagard, Chief Executive Officer and Co-Founder of MaaT Pharma. "Since our successful IPO in November 2021, we have delivered on the key milestones we had defined and we continue to progress, with the ambition to leverage the microbiome for the benefit of millions of patients fighting cancer."

A question-and-answer session will follow the presentations. Please note that all the presentations are in English with French subtitles. The webcast will be made available on the Company’s website after the event.

On May 24, 2022 Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") reported the successful completion of its acquisition of Antares Pharma, Inc. ("Antares") (Press release, Halozyme, MAY 24, 2022, View Source [SID1234614979]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The tender offer for all of the outstanding shares of Antares common stock expired as scheduled at one minute after 11:59 p.m., Eastern Time, on Monday, May 23, 2022. The minimum tender condition and all of the other conditions to the offer have been satisfied and on May 24, 2022, Halozyme accepted for payment and will promptly pay for all shares validly tendered and not validly withdrawn.

Following its acceptance of the tendered shares, Halozyme completed its acquisition of Antares through the merger of a wholly owned subsidiary of Halozyme with and into Antares, pursuant to Section 251(h) of the General Corporation Law of the State of Delaware, with Antares continuing as the surviving corporation and becoming a wholly owned subsidiary of Halozyme.

In connection with the merger, all Antares shares not validly tendered in the tender offer have been converted into the right to receive the same $5.60 per share in cash, without interest thereon and net of any applicable withholding taxes, that would have been paid had such shares been validly tendered in the tender offer. As of May 24, 2022, Antares common stock will cease to be traded on the NASDAQ Global Select Stock Market.

BofA Securities, Inc. and Wells Fargo Securities LLC acted as financial advisors to Halozyme and Weil, Gotshal & Manges LLP acted as legal advisor. Jefferies LLC acted as financial advisor to Antares and Skadden, Arps, Slate, Meagher & Flom LLP acted as legal advisor.